08:34 AM EDT, 06/06/2025 (MT Newswires) -- Novo Nordisk's ( NVO ) obesity and diabetes drug semaglutide potential to lead to a condition that may cause loss of vision is a "very rare side effect," the European Medicines Agency said Friday.

The drug ingredient, sold commercially as Ozempic, Rybelsus and Wegovy, can cause non-arteritic anterior ischemic optic neuropathy in up to one in every 10,000 people who take semaglutide, the agency said.

The agency said it is recommending that semaglutide medicines include the eye ailment as a possible side effect with a frequency of "very rare."

Novo Nordisk's ( NVO ) shares were up more than 2% in recent premarket activity.